LUCD Stock Forecast 2025-2026
Distance to LUCD Price Targets
LUCD Price Momentum
10 Quality Stocks Worth Considering Now
Researching Lucid Diagnostics (LUCD) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on LUCD and similar high-potential opportunities.
Latest LUCD Stock Price Targets & Analyst Predictions
Based on our analysis of 7 Wall Street analysts, LUCD has a bullish consensus with a median price target of $3.00 (ranging from $2.00 to $7.00). The overall analyst rating is Strong Buy (9.3/10). Currently trading at $1.21, the median forecast implies a 147.9% upside. This outlook is supported by 6 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Edward Woo at Ascendiant Capital, projecting a 478.5% upside. Conversely, the most conservative target is provided by Ross Osborn at Cantor Fitzgerald, suggesting a 65.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
LUCD Analyst Ratings
LUCD Price Target Range
Latest LUCD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for LUCD.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 11, 2025 | Needham | Mike Matson | Buy | Reiterates | $3.00 |
| Mar 26, 2025 | Cantor Fitzgerald | Ross Osborn | Overweight | Reiterates | $2.00 |
| Mar 24, 2025 | Needham | Mike Matson | Buy | Maintains | $3.00 |
| Dec 9, 2024 | Ascendiant Capital | Edward Woo | Buy | Maintains | $7.00 |
| Nov 15, 2024 | Cantor Fitzgerald | Ross Osborn | Overweight | Maintains | $2.00 |
| Nov 14, 2024 | Canaccord Genuity | Kyle Mikson | Buy | Maintains | $3.00 |
| Nov 14, 2024 | Needham | Mike Matson | Buy | Reiterates | $2.50 |
| Sep 10, 2024 | Ascendiant Capital | Edward Woo | Buy | Maintains | $7.25 |
| Aug 13, 2024 | Needham | Mike Matson | Buy | Reiterates | $2.50 |
| Aug 13, 2024 | Canaccord Genuity | Kyle Mikson | Buy | Maintains | $3.00 |
| Jun 6, 2024 | Ascendiant Capital | Edward Woo | Buy | Maintains | $7.50 |
| May 15, 2024 | Cantor Fitzgerald | Ross Osborn | Overweight | Reiterates | $3.00 |
| May 13, 2024 | Needham | Mike Matson | Buy | Reiterates | $2.50 |
| Apr 12, 2024 | Needham | Mike Matson | Buy | Reiterates | $2.50 |
| Mar 27, 2024 | Needham | Mike Matson | Buy | Reiterates | $2.50 |
| Mar 27, 2024 | Cantor Fitzgerald | Ross Osborn | Overweight | Maintains | $3.00 |
| Nov 14, 2023 | Needham | Mike Matson | Buy | Maintains | $2.50 |
| Sep 26, 2023 | Cantor Fitzgerald | Ross Osborn | Overweight | Reiterates | $4.00 |
| Aug 22, 2023 | Cantor Fitzgerald | Charles Duncan | Overweight | Reiterates | $4.00 |
| Aug 16, 2023 | Cantor Fitzgerald | Charles Duncan | Overweight | Reiterates | $4.00 |
Lucid Diagnostics Inc. (LUCD) Competitors
The following stocks are similar to Lucid Diagnostics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Lucid Diagnostics Inc. (LUCD) Financial Data
Lucid Diagnostics Inc. has a market capitalization of $127.21M with a P/E ratio of 0.0x. The company generates $4.35M in trailing twelve-month revenue with a -63.3% profit margin.
Revenue growth is +15.1% quarter-over-quarter, while maintaining an operating margin of -1,025.6% and return on equity of -2,956.4%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Lucid Diagnostics Inc. (LUCD) Business Model
About Lucid Diagnostics Inc.
Develops early detection tools for esophageal cancer.
Lucid Diagnostics operates by providing innovative diagnostic solutions, specifically through its flagship product, EsoCheck. The company generates revenue by selling this less invasive alternative to traditional endoscopy, thereby catering to healthcare providers and patients seeking efficient diagnostic methods for esophageal conditions.
The company is positioned within the MedTech industry, focusing on preventative healthcare solutions. By enhancing early diagnosis rates, Lucid Diagnostics aims to improve patient outcomes and increase awareness of non-invasive diagnostic options.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
72
CEO
Dr. Lishan Aklog M.D.
Country
United States
IPO Year
2021
Website
www.luciddx.comLucid Diagnostics Inc. (LUCD) Latest News & Analysis
Lucid Diagnostics: DNA Testing To Get Medicare Coverage, Driving Volumes, Says Bullish Analyst
8 days agoNeedham reports that Lucid Diagnostics Inc. (LUCD) is expected to gain Medicare reimbursement approval for EsoGuard testing, potentially increasing testing volumes.
Approval for EsoGuard Medicare reimbursement would likely increase Lucid Diagnostics' testing volumes, enhancing revenue potential and investor confidence in the company’s growth prospects.
Lucid Diagnostics Inc. closed a public offering of 14.375 million shares at $1.20 each, raising approximately $16.1 million in net proceeds after expenses.
Lucid Diagnostics raised $16.1 million through a public offering, enhancing liquidity for growth initiatives. This could impact stock performance and investor confidence in the company's future.
Lucid Diagnostics Inc. (Nasdaq: LUCD) plans to offer shares of common stock in an underwritten public offering and may grant underwriters a 45-day option for additional shares.
Lucid Diagnostics' stock offering could dilute existing shares, impacting share value. The funding may also signal growth potential, affecting investor sentiment and future valuations.
Lucid Diagnostics Inc. (Nasdaq: LUCD) announced a public offering of 12.5 million shares at $1.20 each, with an option for underwriters to buy an additional 1.875 million shares.
Lucid Diagnostics' public offering may dilute existing shares, impact stock price, and signal capital needs, affecting investor sentiment and future growth prospects.
Lucid Diagnostics to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
16 days agoLucid Diagnostics Inc. (Nasdaq: LUCD) CEO Lishan Aklog will speak at the 24th Annual Needham Virtual Healthcare Conference on April 10, 2025, at 11:00 AM EDT.
Lucid Diagnostics' CEO speaking at a major healthcare conference highlights the company's visibility and potential growth in the cancer diagnostics market, influencing investor sentiment and stock performance.
Lucid Diagnostics Inc. will launch the "Embrace the Future" campaign for its EsoCheck® device during Esophageal Cancer Awareness Month and at the DDW 2025 conference in May.
Lucid Diagnostics is launching a campaign to promote its EsoCheck® device during a key medical conference, potentially increasing visibility and adoption among gastroenterologists, impacting revenue growth.
Frequently Asked Questions About LUCD Stock
What is Lucid Diagnostics Inc.'s (LUCD) stock forecast for 2025?
Based on our analysis of 7 Wall Street analysts, Lucid Diagnostics Inc. (LUCD) has a median price target of $3.00. The highest price target is $7.00 and the lowest is $2.00.
Is LUCD stock a good investment in 2025?
According to current analyst ratings, LUCD has 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.21. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for LUCD stock?
Wall Street analysts predict LUCD stock could reach $3.00 in the next 12 months. This represents a 147.9% increase from the current price of $1.21. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Lucid Diagnostics Inc.'s business model?
Lucid Diagnostics operates by providing innovative diagnostic solutions, specifically through its flagship product, EsoCheck. The company generates revenue by selling this less invasive alternative to traditional endoscopy, thereby catering to healthcare providers and patients seeking efficient diagnostic methods for esophageal conditions.
What is the highest forecasted price for LUCD Lucid Diagnostics Inc.?
The highest price target for LUCD is $7.00 from Edward Woo at Ascendiant Capital, which represents a 478.5% increase from the current price of $1.21.
What is the lowest forecasted price for LUCD Lucid Diagnostics Inc.?
The lowest price target for LUCD is $2.00 from Ross Osborn at Cantor Fitzgerald, which represents a 65.3% increase from the current price of $1.21.
What is the overall LUCD consensus from analysts for Lucid Diagnostics Inc.?
The overall analyst consensus for LUCD is bullish. Out of 7 Wall Street analysts, 6 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $3.00.
How accurate are LUCD stock price projections?
Stock price projections, including those for Lucid Diagnostics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.